Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study.
hepatic resection
infiltrative hepatocellular carcinoma
transarterial chemoembolization
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
01
2020
revised:
20
03
2020
accepted:
26
03
2020
pubmed:
5
4
2020
medline:
31
7
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
Prognosis of infiltrative hepatocellular carcinoma (iHCC) is poor, and the treatments selection based on efficacy is unclear. We performed this multicenter study to compare the efficacy of hepatic resection and transarterial chemoembolization (TACE) in treating patients with iHCC. We retrospectively analyzed the overall survivals (OS) in 319 patients with iHCC who were initially treated by hepatic resection (n = 133) or TACE (n = 186) at four tertiary centers. Fifty-eight patients in the TACE group were assessed as resectable and compared with the hepatic resection group in subgroup analysis. A propensity score matched (PSM) analysis was performed to reduce selection bias. Cox regression was performed to identify significant factors associated with OS. The median OS time was significantly longer in the hepatic resection group than that in the TACE group, before and after PSM (before PSM, 17.5 vs 7.3 months, P < 0.0001; after PSM, 14.0 vs 7.3 months, P < 0.0001). The multivariable analysis indicated TACE as a risk factor of OS (hazard ratio = 2.233, 95% confidence interval = 1.492 to 3.341, P < 0.0001), as well as portal venous tumor thrombosis grades 3-4 and alpha fetal protein (AFP) > 400 ng/mL. In the subgroup analysis, the better efficacy of hepatic resection over TACE persisted regardless of the grade of portal venous tumor thrombosis and the level of AFP. As for resectable patients, hepatic resection still showed significant survival benefit (before PSM, 17.5 vs 11.2 months, P = 0.0013; after PSM, 14.0 vs 10.9 months, P = 0.0304). Hepatic resection might be the better choice for patients with iHCC due to its better survival benefit than TACE.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Prognosis of infiltrative hepatocellular carcinoma (iHCC) is poor, and the treatments selection based on efficacy is unclear. We performed this multicenter study to compare the efficacy of hepatic resection and transarterial chemoembolization (TACE) in treating patients with iHCC.
METHODS
METHODS
We retrospectively analyzed the overall survivals (OS) in 319 patients with iHCC who were initially treated by hepatic resection (n = 133) or TACE (n = 186) at four tertiary centers. Fifty-eight patients in the TACE group were assessed as resectable and compared with the hepatic resection group in subgroup analysis. A propensity score matched (PSM) analysis was performed to reduce selection bias. Cox regression was performed to identify significant factors associated with OS.
RESULTS
RESULTS
The median OS time was significantly longer in the hepatic resection group than that in the TACE group, before and after PSM (before PSM, 17.5 vs 7.3 months, P < 0.0001; after PSM, 14.0 vs 7.3 months, P < 0.0001). The multivariable analysis indicated TACE as a risk factor of OS (hazard ratio = 2.233, 95% confidence interval = 1.492 to 3.341, P < 0.0001), as well as portal venous tumor thrombosis grades 3-4 and alpha fetal protein (AFP) > 400 ng/mL. In the subgroup analysis, the better efficacy of hepatic resection over TACE persisted regardless of the grade of portal venous tumor thrombosis and the level of AFP. As for resectable patients, hepatic resection still showed significant survival benefit (before PSM, 17.5 vs 11.2 months, P = 0.0013; after PSM, 14.0 vs 10.9 months, P = 0.0304).
CONCLUSION
CONCLUSIONS
Hepatic resection might be the better choice for patients with iHCC due to its better survival benefit than TACE.
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2220-2228Subventions
Organisme : National Science Fund for Distinguished Young Scholars
ID : 81825013
Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Eggel H. Uber das primare Carcinom der Leber: Beitr Pathol Anat Allerg Pathol., 1901.
Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110-115.
Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J. Magn. Reson. Imaging 2003; 18: 189-195.
Trevisani F, Caraceni P, Bernardi M et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72: 1557-1563.
Sereni CP, Rodgers SK, Kirby CL, Goykhman I. Portal vein thrombus and infiltrative HCC: a pictoral review. Abdom. Radiol. (NY) 2017; 42: 159-170.
Demirjian A, Peng P, Geschwind JF et al. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J. Gastrointest. Surg. 2011; 15: 2089-2097.
Kneuertz PJ, Demirjian A, Firoozmand A et al. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann. Surg. Oncol. 2012; 19: 2897-2907.
Yopp AC, Mokdad A, Zhu H et al. Infiltrative hepatocellular carcinoma: natural history and comparison with multifocal, nodular hepatocellular carcinoma. Ann. Surg. Oncol. 2015; 22: S1075-S1082.
Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2013; 11: 572-578.
Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314.
Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-1700.e3.
Vitale A, Burra P, Frigo AC et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J. Hepatol. 2015; 62: 617-624.
Zhong JH, Ke Y, Gong WF et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 2014; 260: 329-340.
Yan X, Fu X, Deng M et al. Infiltrative hepatocellular carcinoma: assessment of factors associated with outcomes in patients undergoing hepatectomy. Medicine (Baltimore) 2016; 95: e3589.
Ochiai T, Sonoyama T, Ichikawa D et al. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J. Cancer Res. Clin. Oncol. 2004; 130: 197-202.
Elsayes KM, Hooker JC, Agrons MM et al. 2017 Version of LI-RADS for CT and MR imaging: an update. Radiographics 2017; 37: 1994-2017.
Lopez RR Jr, Pan SH, Hoffman AL et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch. Surg. 2002; 137: 653-657 discussion 657-8.
Koulakian H, Allaham W, Vilgrain V, Ronot M. Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response? Eur. Radiol. 2018.
Kudo M, Izumi N, Kokudo N et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 2011; 29: 339-364.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004; 240: 205-213.
Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute 2009;4.
Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
Liu PH, Hsia CY, Lee YH et al. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J. Surg. Oncol. 2015; 111: 404-409.
Hung TH, Tsai CC, Lin CC, Lee HF, Chu CJ, Lin HC. Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma? Hepatol. Int. 2013; 7: 676-682.
Han K, Kim JH, Yoon HM et al. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival. Korean J. Radiol. 2014; 15: 464-471.
Jang ES, Yoon JH, Chung JW et al. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J. Cancer Res. Clin. Oncol. 2013; 139: 635-643.
Hyun MH, Lee YS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology 2018; 68: 977-993.
Shindoh J, Makuuchi M, Matsuyama Y et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J. Hepatol. 2016; 64: 594-600.
Xu L, Peng ZW, Chen MS et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J. Hepatol. 2015; 63: 122-130.
Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012; 118: 4725-4736.
Zhang XP, Wang K, Li N et al. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer 2017; 17: 902.
Zhang XP, Gao YZ, Chen ZH et al. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology 2019; 69: 2076-2090.
Riaz A, Ryu RK, Kulik LM et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J. Clin. Oncol. 2009; 27: 5734-5742.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. 2018; 69: 182-236.
Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J. Gastroenterol. 2006; 12: 7561-7567.
Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J. Surg. 2014; 38: 490-496.
Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J. Gastroenterol. 2016; 22: 7289-7300.
Marrero JA, Kulik LM, Sirlin C et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018.
Yang J, Yang JY, Yan LN, Wen TF, Li B, Wang WT. Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. Dig. Liver Dis. 2018; 50: 713-719.
Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J. Hepatobiliary Pancreat. Surg. 2005; 12: 16-22.
Lin XJ, Yang J, Chen XB, Zhang M, Xu MQ. The critical value of remnant liver volume-to-body weight ratio to estimate posthepatectomy liver failure in cirrhotic patients. J. Surg. Res. 2014; 188: 489-495.
?A3B2 twb=.4w?>Truant S, Boleslawski E, Sergent G et al. Liver function following extended hepatectomy can be accurately predicted using remnant liver volume to body weight ratio. World J. Surg. 2015; 39: 1193-1201.